Fig. 2.
ASB2-induced degradation of FLNa in myeloid leukemia cells. PLB985, PLB985/MT-FLAG, PLB985/MT-FLAG-ASB2wt, and PLB985/MT-FLAG-ASB2LA cells were left untreated (−) or were treated (+) with 100 μm ZnSO4 (Zn) for 8 h. A, schematic representation of ASB2wt and ASB2LA constructs under the control of the zinc-inducible MT promoter. The BC box mutation is indicated in bold. B, autoradiograms of mRNA of ASB2 (upper panel), FLNa (middle panel), and Arbp as an assessment of RNA quantities in each lane (lower panel). C, proteins of cytosolic extracts (15 μg) were separated by SDS-PAGE and immunoblotted for ASB2, FLNa, and non-muscle myosin heavy chain IIA (NM Myosin IIA). SOCS, suppressor of cytokine signaling.